JP7665215B2 - 腸のニューロパチーを治療するためのグリア細胞株由来神経栄養因子（ｇｄｎｆ）の使用 - Google Patents

腸のニューロパチーを治療するためのグリア細胞株由来神経栄養因子（ｇｄｎｆ）の使用 Download PDF

Info

Publication number
JP7665215B2
JP7665215B2 JP2022538283A JP2022538283A JP7665215B2 JP 7665215 B2 JP7665215 B2 JP 7665215B2 JP 2022538283 A JP2022538283 A JP 2022538283A JP 2022538283 A JP2022538283 A JP 2022538283A JP 7665215 B2 JP7665215 B2 JP 7665215B2
Authority
JP
Japan
Prior art keywords
pharmaceutical composition
gdnf
use according
enteric
hscr
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
JP2022538283A
Other languages
English (en)
Japanese (ja)
Other versions
JP2023515915A5 (cg-RX-API-DMAC7.html
JP2023515915A (ja
Inventor
ロドルフ・ソレ
ニコラ・ピロン
Original Assignee
トランスフェルト・プラス・ソシエテ・アン・コマンディテ
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by トランスフェルト・プラス・ソシエテ・アン・コマンディテ filed Critical トランスフェルト・プラス・ソシエテ・アン・コマンディテ
Publication of JP2023515915A publication Critical patent/JP2023515915A/ja
Publication of JP2023515915A5 publication Critical patent/JP2023515915A5/ja
Application granted granted Critical
Publication of JP7665215B2 publication Critical patent/JP7665215B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/18—Growth factors; Growth regulators
    • A61K38/185—Nerve growth factor [NGF]; Brain derived neurotrophic factor [BDNF]; Ciliary neurotrophic factor [CNTF]; Glial derived neurotrophic factor [GDNF]; Neurotrophins, e.g. NT-3
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0031—Rectum, anus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P41/00—Drugs used in surgical methods, e.g. surgery adjuvants for preventing adhesion or for vitreum substitution

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Biomedical Technology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Psychology (AREA)
  • Zoology (AREA)
  • Immunology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Surgery (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
JP2022538283A 2019-12-19 2020-12-18 腸のニューロパチーを治療するためのグリア細胞株由来神経栄養因子（ｇｄｎｆ）の使用 Active JP7665215B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201962950781P 2019-12-19 2019-12-19
US62/950,781 2019-12-19
PCT/CA2020/051746 WO2021119827A1 (en) 2019-12-19 2020-12-18 Use of glial cell line-derived neurotrophic factor (gdnf) for the treatment of enteric neuropathies

Publications (3)

Publication Number Publication Date
JP2023515915A JP2023515915A (ja) 2023-04-17
JP2023515915A5 JP2023515915A5 (cg-RX-API-DMAC7.html) 2023-12-13
JP7665215B2 true JP7665215B2 (ja) 2025-04-21

Family

ID=76476522

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2022538283A Active JP7665215B2 (ja) 2019-12-19 2020-12-18 腸のニューロパチーを治療するためのグリア細胞株由来神経栄養因子（ｇｄｎｆ）の使用

Country Status (6)

Country Link
US (1) US20230022970A1 (cg-RX-API-DMAC7.html)
EP (1) EP4076499B1 (cg-RX-API-DMAC7.html)
JP (1) JP7665215B2 (cg-RX-API-DMAC7.html)
CA (1) CA3162011A1 (cg-RX-API-DMAC7.html)
ES (1) ES3036928T3 (cg-RX-API-DMAC7.html)
WO (1) WO2021119827A1 (cg-RX-API-DMAC7.html)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20240366723A1 (en) * 2021-06-16 2024-11-07 Transfert Plus, Limited Partnership Combination therapy for the treatment of enteric neuropathies

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4179337A (en) 1973-07-20 1979-12-18 Davis Frank F Non-immunogenic polypeptides
JPS6023084B2 (ja) 1979-07-11 1985-06-05 味の素株式会社 代用血液
US4640835A (en) 1981-10-30 1987-02-03 Nippon Chemiphar Company, Ltd. Plasminogen activator derivatives
US4496689A (en) 1983-12-27 1985-01-29 Miles Laboratories, Inc. Covalently attached complex of alpha-1-proteinase inhibitor with a water soluble polymer
EP0206448B1 (en) 1985-06-19 1990-11-14 Ajinomoto Co., Inc. Hemoglobin combined with a poly(alkylene oxide)
US4791192A (en) 1986-06-26 1988-12-13 Takeda Chemical Industries, Ltd. Chemically modified protein with polyethyleneglycol
US6184200B1 (en) * 1995-09-28 2001-02-06 Amgen Inc. Truncated glial cell line-derived neurotrophic factor
EP0922446A1 (en) 1997-12-03 1999-06-16 Applied Research Systems Ars Holding N.V. Solution-phase site-specific preparation of GRF-PEG conjugates
CA2422707A1 (en) 2000-10-05 2002-04-11 Ares Trading S.A. Regioselective liquid phase pegylation
BR0206919A (pt) 2001-02-02 2004-07-06 Conjuchem Inc Derivados de fator de liberação de hormÈnio de crescimento de longa duração
UA112981C2 (uk) * 2011-04-11 2016-11-25 Елі Ліллі Енд Компані Варіант людського gdnf
US20160045487A1 (en) * 2013-03-27 2016-02-18 Childeren's Medical Center Corporation Compositions and methods for treating neuropathy
EP3414322A4 (en) * 2015-12-23 2020-03-04 Memorial Sloan-Kettering Cancer Center CELL THERAPY AND DRUG DISCOVERY BASED ON CELL LINES DERIVED FROM HUMAN ENTERAL NEURAL CREST DERIVED FROM PLURIPOTENT STEM CELLS

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
Neurogastroenterology and Motility，2019年08月，31(Supplement 4)，p.128, Abstract 251

Also Published As

Publication number Publication date
EP4076499A4 (en) 2023-11-01
EP4076499B1 (en) 2025-07-16
EP4076499A1 (en) 2022-10-26
ES3036928T3 (en) 2025-09-25
JP2023515915A (ja) 2023-04-17
EP4076499C0 (en) 2025-07-16
US20230022970A1 (en) 2023-01-26
WO2021119827A1 (en) 2021-06-24
CA3162011A1 (en) 2021-06-24

Similar Documents

Publication Publication Date Title
CN113614222A (zh) 体外人血脑屏障
CN101600461B (zh) 通过干细胞营养物进行的器官的形成和复壮以及酒精损伤的器官的再生
Furuno et al. Cell adhesion molecule 1 (CADM1) on mast cells promotes interaction with dorsal root ganglion neurites by heterophilic binding to nectin-3
KR20190051837A (ko) 중뇌 유래의 성상교세포와 도파민 신경줄기세포의 공동 이식에 의한 도파민 신경세포의 이식 치료 효과 개선
Ma et al. C-type natriuretic peptide functions as an innate neuroprotectant in neonatal hypoxic-ischemic brain injury in mouse via natriuretic peptide receptor 2
WO2007149554A2 (en) Methods for restoring neural function
JP7665215B2 (ja) 腸のニューロパチーを治療するためのグリア細胞株由来神経栄養因子（ｇｄｎｆ）の使用
US20240366723A1 (en) Combination therapy for the treatment of enteric neuropathies
Barton Regulation of the Gut-Brain Axis by Guanylyl Cyclase C
Wang et al. VDAC1 oligomerization activates PANoptosis via mtDNA-STING axis in age-related macular degeneration
Souchkova et al. A MOLECULAR-BASED REGENERATIVE MEDICINE APPROACH FOR THE TREATMENT OF HIRSCHSPRUNG DISEAS
Shamloo Pathogenesis of Dry Eye in Graft Versus Host Disease (GVHD): Role of Ocular Mucins and Conjunctival Fibrosis
Kowalkowski Intestinal Atresias and Development with a Focus on the Fibroblast Growth Factor Receptor 2IIIb Mouse Model
Krishna Chandran MÜLLER GLIAL CELLS IN EPIRETINAL MEMBRANE FORMATION
Wu Heterodimer of erythropoietin receptor and β common receptor in renal ischemia-reperfusion injury and repair
Talsma Dissecting the Roles of Macrophage Subpopulations Responding to Peripheral Nerve Injury in Conditioning-Lesion Enhanced Regeneration in vivo
Moghimyfiroozabad C1QL1 & c-KIT molecular complexes: cell surface signaling pathways acting at neuronal synapses and beyond
Bauch Differentiation, Myelination, and Remyelination of Oligodendroglia and the role of ECM molecules
Maset Altered migration of forebrain inhibitory interneurons in a mouse model of intellectual disability
Bourgeois A Role for Abelson Helper Integration Site-1 (AHI1) in Murine Muscular Development and Function Independent of the Central Nervous System
Shahid Functional compensation among metabotropic receptors involved in cytosolic Ca^< 2+> signaling and satiety control mechanisms
CN119403563A (zh) 治疗剂和方法
Wahlin Molecular dynamics of photoreceptor synaptogenesis in the developing chick retina
MacLean ATP elicits electrophysiological and migratory responses in cells of the spinal cord stem cell niche
JPWO2009044787A1 (ja) テノモジュリンを有効成分とする腱断裂性疾患治療剤

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20230303

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20231204

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20231204

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20241125

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20250225

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20250304

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20250402

R150 Certificate of patent or registration of utility model

Ref document number: 7665215

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150